“Pharmacoeconomic aspects of warfarin and new oral anticoagulants use as prevention of thromboembolic complications in patients with atrial fibrillation”, UJC, vol. 27, no. 4, pp. 45–53, Oct. 2020, doi: 10.31928/1608-635X-2020.4.4553.